Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The candidate malaria vaccine RTS,S/AS01(E) provides significant but partial protection from clinical malaria. On in vitro circumsporozoite protein (CSP) peptide stimulation and intra-cellular cytokine staining of whole blood taken from 407 5-17 month-old children in a phase IIb trial of RTS,S/AS01(E), we identified significantly increased frequencies of two CSP-specific CD4+ T cells phenotypes among RTS,S/AS01(E) vaccinees (IFNγ-IL2+TNF- and IFNγ-IL2+TNF+ CD4+ T cells), and increased frequency of IFNγ-IL2-TNF+ CD4+ T cells after natural exposure. All these T cells phenotypes were individually associated with reductions in the risk of clinical malaria, but IFNγ-IL2-TNF+ CD4+ T cells independently predicted reduced risk of clinical malaria on multi-variable analysis (HR = 0.29, 95% confidence intervals 0.15-0.54, p<0.0005). Furthermore, there was a strongly significant synergistic interaction between CSP-specific IFNγ-IL2-TNF+ CD4+ T cells and anti-CSP antibodies in determining protection against clinical malaria (p = 0.002). Vaccination strategies that combine potent cellular and antibody responses may enhance protection against malaria.

Original publication

DOI

10.1371/journal.pone.0052870

Type

Journal article

Journal

PLoS One

Publication Date

2012

Volume

7

Keywords

Antibodies, Protozoan, Antibody Formation, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Clinical Trials, Phase II as Topic, Cytokines, Humans, Infant, Kaplan-Meier Estimate, Malaria Vaccines, Malaria, Falciparum, Plasmodium falciparum, Proportional Hazards Models, Protozoan Proteins, Randomized Controlled Trials as Topic, Risk, Sporozoites, Vaccination